PAK4-mediated CEBPB activation upregulates CLDN4 expression to promote cell migration and invasion in breast cancer, thus, PAK4/CEBPB/CLDN4 may be a potential therapeutic target in breast cancer treatment. Here, PAK4 is linked to breast carcinoma.